Kai KupferschmidtScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.One of the world’s biggest trials of COVID-19 therapies released its long-awaited interim results yesterday—and they’re a letdown.
None of the four treatments in the Solidarity trial, which enrolled more than 11,000 patients in 400 hospitals around the globe, increased survival—not even the much-touted antiviral drug remdesivir.